NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Trading window closed for the Designated Persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time with effect from Wednesday July 1, 2020 to till 48 hours after the declaration of the Financial Results of the Company for the quarter ended on 30th June, 2020.
Buy Natco Pharma; target of Rs 740: ICICI Direct
ICICI Direct is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 740 in its research report dated June 19, 2020.
Earnings Call Transcript - Q4FY20 for Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript. Call Participants: Mr. Rajeev Nannapaneni - Vice Chairman and Chief Executive Officer, Mr. Rajesh Chebiyam - Vice President, Acquisitions, Institutional Investor Management and Corporate Communications Introductory remarks from Rajesh Chebiyam Good morning, and welcome, everyone, to NATCO's conference call discussing our earnings results for the fourth quarter and full year FY2020. I hope all of you have been staying safe during this unprecedented, stressful Covid-19 situation. Regarding the earnings details, we hope you have received financials in the press release which we sent out yesterday and is also present on our website. For FY20, NATCO recorded consolidated total revenue of Rs 2,022.4 crore as against Rs 2,224.7 crore, a decline of 9% YoY The net profit for the period, on a consolidated basis, was Rs 458.1 crore, as against Rs 642.4 crore last year, showing a decline of about 29% For the fourth quarter ended March 31, 2020, the company recorded a net revenue of Rs 477.2 crore, on a consolidated basis, which is almost flat as compared to Rs 486.7 crore during Q4, FY 2019 The profit after tax, on a consolidated basis, was recorded as Rs 93.2 crore for the quarter, as against Rs 120.4 crore in the same quarter last year The overall decline in revenue and profits, from prior year, was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures The company also faced slowdown in business operations during the fourth quarter due to supply chain issues amidst Covid-19 concerns, which were subsequently resolved Even though lockdown was in the later part of March, a lot of people were uncomfortable coming for treatments to the hospital because there was a risk as most cancer patients have immunosuppression so they could lead to Covid-19 infection. We have seen that it has been playing out in March, April and May and June as well If you look at the onco portfolio, because of people not coming out, there was an initial fall in sales but things are picking up now specially on the oral onco, the sale has become more stable now. But, we have seen a lot of pressure on the chemo side. People are not coming back at the same level as they used to. The fear of infection continues so there is some pressure in the domestic business especially with the hospital related There was a pricing pressure for overall 2019-20 but now pricing factor is not involved. It is now Covid-19. There was overall decline full year and the primary reason for the drop in the sale was because of the pricing pressure. The secondary factor playing now is Covid-19 and Covid-19 specifically to the chemo products. Our portfolio has both oral products if you can take it home and chemo products which are taken in hospitals. The oral tablets have sort of rebounded now as it is seeing more stability and things have settled down. But where this is going, I have no idea like no one else. If you ask me if there is lower demand, yes there is lower demand We have seen a decline of Rs 400 crore but that's a very unusual portfolio. Because of Covid-19, normal people are coming and getting tested because of hospitalisation pressure. The impact is less now. When we were degrowing earlier, impact was more then Total domestic formulation sale was Rs 540 crore for the year and oncology recorded about Rs 308 crores and the non-onco related recorded Rs 117 crores. CND did about Rs 45 crores which is a significant jump as we had almost zero sales a year and a half ago. We are doing well About 60-65% revenue stands for oral and 30-35% tends to be chemo, typically as per a rough estimation For Canada, we are scheduled for a trial in the first week of July We are anticipating approval shortly for RT PCR. We filed it 9 months ago. I don’t know how much time approval will take but it's doing well. There is nothing much to report on the court case during this time There is some dependence on China for API but not to that extent. Whatever government has announced in terms of incentives is for specialty chemicals business which we are not in During this year again, we have an extensive portfolio. We launched about 10 products last year and are planning to launch around 8-10 products this year too. It is a challenging time to launch in Covid-19 as the ability to meet the doctor is limited as all doctors have not come back but we are optimistic that the things will improve except in the containment zones. Overall, I am fairly bullish and expect domestic business should grow but it is little hard to say that how much it will grow Natco Pharma share price falls 3% post Q4 earnings
For the latest quarter, the company's net profit stood at Rs 94.1 crore, down 22.1% from Rs 120.80 crore in the corresponding quarter NATCO PHARMA LTD. - 524816 - Fixed Record Date As 29Th June, 2020
Fixed Record date as 29th June, 2020 for payment of 4th Interim Dividend NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO records INR 2,022.4 Crore consolidated revenue and INR 458.1 Crore of profit, after tax, for the full year ended March 2020 NATCO PHARMA LTD. - 524816 - Board declares Fourth Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 17, 2020, inter alia, has considered and approved the following:- Declaration of fourth (4th) interim dividend of Rs. 1/- per equity share of Rs .2/- each for the financial year 2019-20. The said interim dividend will be paid on or before July 05, 2020. NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earning call for Q4 and year ended FY20